4-羧酸甲酯-2-硝基苯硼酸 | 85107-55-7

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羧酸甲酯-2-硝基苯硼酸
• 中文别名: (2-硝基-4-甲酸甲酯)苯硼酸；2-硝基-4-甲氧羰基苯硼酸；4-甲氧羰基-2-硝基苯硼酸；4-甲氧基羰基-2-硝基苯硼酸；4-甲氧羰基-2-硝基苯基硼酸；2-硝基-4-羧酸甲酯苯硼酸；4-羧基甲酯-2-硝基苯硼酸
• 英文名称: 4-(methoxycarbonyl)-2-nitrophenylboronic acid
• 英文别名: 4-Methoxycarbonyl-2-nitrophenylboronic acid；(4-methoxycarbonyl-2-nitrophenyl)boronic acid
• CAS: 85107-55-7
• 化学式: C₈H₈BNO₆
• mdl: MFCD01632202
• 分子量: 224.966
• InChiKey: SFEJGHJCGQNFQC-UHFFFAOYSA-N

物化性质

• 熔点：
  160-171°C
• 沸点：
  441.0±55.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.74
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Methoxycarbonyl-2-nitrophenylboronic acid
Product Name:
Synonyms: Methyl 4-borono-3-nitrobenzoate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Methoxycarbonyl-2-nitrophenylboronic acid
Ingredient name:
CAS number: 85107-55-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BNO6
Molecular weight: 225.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羧酸甲酯-2-硝基苯硼酸 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 邻二氯苯 为溶剂， 反应 38.0h， 生成 methyl 9-benzyl-5-cyano-7-(3,5-dimethyl-4-isoxazolyl)-9H-carbazole-2-carboxylate
  参考文献：
  名称：

  Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c00625
• 作为产物：
  描述：

  4-碘-3-硝基苯甲酸甲酯 在 盐酸 、 苯基氯化镁 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.58h， 生成 4-羧酸甲酯-2-硝基苯硼酸
  参考文献：
  名称：

  Promoting Reductive Tandem Reactions of Nitrostyrenes with Mo(CO)₆ and a Palladium Catalyst To Produce 3H-Indoles

  摘要：

  The combination of Mo(CO)(6) and 10 Mol % of palladium acetate catalyzes the transformation of 2-nitroarenes to 3H-indoles through a tandem cyclization-[1,2] shift reaction of in situ generated nitrosoarenes. Mo(CO)(6) appears to have dual roles in this transformation generate generate CO and promote C-N bond formation to increase the yield of the N-heterocycle product.

  DOI：

  10.1021/jacs.5b02946
• 作为试剂：
  描述：

  5-溴-2-碘苯甲腈 、 4-羧酸甲酯-2-硝基苯硼酸 、 Tripotassium;phosphate 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 氮气 、 4-羧酸甲酯-2-硝基苯硼酸 、 水 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 20.0h， 以to give methyl 4′-bromo-2′-cyano-2-nitro-[1,1′-biphenyl]-4-carboxylate (2.85 g, 7.89 mmol, 81% yield) as a tan solid的产率得到methyl 4′-bromo-2′-cyano-2-nitro-[1,1′-biphenyl]-4-carboxylate
  参考文献：
  名称：

  US20140256700A1

  摘要：

  公开号：

文献信息

• The Suzuki–Miyaura Cross‐Coupling as the Key Step in the Synthesis of 2‐Aminobiphenyls and 2,2'‐Diaminobiphenyls: Application in the Synthesis of Schiff Base Complexes of Zn
  作者：Knut Tormodssønn Hylland、Sigurd Øien‐Ødegaard、Mats Tilset

  DOI：10.1002/ejoc.202000599

  日期：2020.7.23

  The Suzuki–Miyaura reaction is used as a key step for the synthesis of 2‐aminobiphenyls and 2,2'‐diaminobiphenyls, which in turn can be utilized to make Schiff base complexes of Zn. Special emphasis is on the cross‐coupling reaction between 2‐bromoanilines and a 2‐nitro‐substituted arylboronic acid, for which there is little existing precedence.

  Suzuki-Miyaura反应被用作合成2-氨基联苯和2,2'-二氨基联苯的关键步骤，而这些反过来又可用于制备Zn的席夫碱配合物。特别强调的是2-溴苯胺与2-硝基取代的芳基硼酸之间的交叉偶联反应，目前尚无此类研究。
• Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride
  作者：Pouria H. Jalily、Jodene Eldstrom、Scott C. Miller、Daniel C. Kwan、Sheldon S. -H. Tai、Doug Chou、Masahiro Niikura、Ian Tietjen、David Fedida

  DOI：10.1124/mol.115.102731

  日期：2016.8

  The increasing prevalence of influenza viruses with resistance to approved antivirals highlights the need for new anti-influenza therapeutics. Here we describe the functional properties of hexamethylene amiloride (HMA)–derived compounds that inhibit the wild-type and adamantane-resistant forms of the influenza A M2 ion channel. For example, 6-(azepan-1-yl)- N -carbamimidoylnicotinamide ( 9 ) inhibits amantadine-sensitive M2 currents with 3- to 6-fold greater potency than amantadine or HMA (IC50 = 0.2 vs. 0.6 and 1.3 µ M, respectively). Compound 9 competes with amantadine for M2 inhibition, and molecular docking simulations suggest that 9 binds at site(s) that overlap with amantadine binding. In addition, tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 27 ) acts both on adamantane-sensitive and a resistant M2 variant encoding a serine to asparagine 31 mutation (S31N) with improved efficacy over amantadine and HMA (IC50 = 0.6 µ M and 4.4 µ M, respectively). Whereas 9 inhibited in vitro replication of influenza virus encoding wild-type M2 (EC50 = 2.3 µ M), both 27 and tert -butyl 4′-(carbamimidoylcarbamoyl)-2′,3-dinitro-[1,1′-biphenyl]-4-carboxylate ( 26 ) preferentially inhibited viruses encoding M2(S31N) (respective EC50 = 18.0 and 1.5 µ M). This finding indicates that HMA derivatives can be designed to inhibit viruses with resistance to amantadine. Our study highlights the potential of HMA derivatives as inhibitors of drug-resistant influenza M2 ion channels.

  对核准抗病毒药物产生耐药性的流感病毒日益增多,这凸显了开发新型抗流感药物的必要性。本文描述了六亚甲基氨氯吡嗪(HMA)衍生物的功能特性,它们能抑制A型流感M2离子通道的野生型和金刚烷胺耐药型。例如, 6-( 唑戊吡嗪-1-吡啦达)-N-甲甲喷达吡嗪-氨酸胺(9)对金刚烷胺敏感的M2离子通道电流的抑制效力比金刚烷胺或HMA高3至6倍(IC50分别为0.2、0.6和1.3μM)。化合物9与金刚烷胺竞争抑制M2, 分子对接模拟显示9结合在金刚烷胺结合位点的重叠处。此外, 二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(27)既对敏感型M2有效, 也对编码丝氨酸31突变为天冬酰胺(S31N)的耐药型M2变种有效, 且效力优于金刚烷胺和HMA(IC50分别为0.6μM和4.4μM)。虽然9抑制了编码野生型M2的流感病毒的体外复制(EC50=2.3μM), 但27和二（伞形酮基羰基）-2',3-二硝基-[1,1'-苄基]-4-羧酸替丁酯(26)更倾向于抑制编码M2(S31N)的病毒(各自的EC50分别为18.0和1.5μM)。这一发现表明,可以设计HMA衍生物来抑制金刚烷胺耐药的病毒。我们的研究强调了HMA衍生物作为耐药性流感M2离子通道抑制剂的潜力。
• Synthesis of 2-amino-4-(methoxycarbonyl)Phenylboronic Acid Hydrochloride, a key Intermediate for the Synthesis of Quinolines Derivatives
  作者：Feng Xue、Chang-Gong Li、Yong Zhu、Tian-Jun Lou

  DOI：10.3184/174751914x14175346572646

  日期：2014.12

  A practical and efficient process for the synthesis in good yield of 2-amino-4-(methoxycarbonyl)phenylboronic acid hydrochloride from p-bromo toluene has been developed via borylation, oxidation, nitration, esterification and hydrogenation.

  通过硼酸化、氧化、硝化、酯化和加氢，开发了一种从对溴甲苯中高产率合成2-氨基-4-(甲氧基羰基)苯基硼酸盐酸盐的实用且有效的方法。
• [EN] BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS<br/>[FR] COMPOSÉS DÉRIVÉS DE CYCLOHEXÈNE BIARYLE-SUBSTITUÉ OU BIARYLE HÉTÉROCYCLIQUE-SUBSTITUÉ EN TANT QU'INHIBITEURS DE CETP
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2014119947A1

  公开（公告）日：2014-08-07

  The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.

  本发明提供了双芳基或杂环双芳基取代的环己烯衍生物化合物，其异构体或药学上可接受的盐。本发明的化合物显示出一种CETP抑制作用，能够增加HDL-胆固醇水平并降低LDL-胆固醇水平。包含这些化合物的药物组合物对于预防或治疗血脂异常或与血脂异常相关的疾病是有用的。
• TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160152628A1

  公开（公告）日：2016-06-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。